Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by AQR Capital Management LLC

AQR Capital Management LLC increased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 39.9% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 71,235 shares of the company’s stock after acquiring an additional 20,318 shares during the period. AQR Capital Management LLC’s holdings in Elanco Animal Health were worth $1,028,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Benjamin F. Edwards & Company Inc. raised its stake in Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares during the period. nVerses Capital LLC acquired a new stake in Elanco Animal Health during the second quarter worth about $32,000. ORG Partners LLC purchased a new position in shares of Elanco Animal Health in the 2nd quarter worth about $31,000. Global Financial Private Client LLC acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at about $72,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Elanco Animal Health during the 1st quarter worth approximately $167,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 100,000 shares of Elanco Animal Health stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the purchase, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. The trade was a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Michael J. Harrington acquired 3,500 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were purchased at an average cost of $14.85 per share, with a total value of $51,975.00. Following the completion of the transaction, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jeffrey N. Simmons bought 100,000 shares of the business’s stock in a transaction on Monday, August 12th. The stock was bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the transaction, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. This represents a 200.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by insiders.

Elanco Animal Health Price Performance

NYSE ELAN opened at $14.34 on Friday. The company’s 50 day simple moving average is $14.38 and its 200 day simple moving average is $14.99. Elanco Animal Health Incorporated has a 12 month low of $8.52 and a 12 month high of $18.80. The firm has a market capitalization of $7.09 billion, a PE ratio of -5.62, a P/E/G ratio of 1.53 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The company had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the firm earned $0.18 earnings per share. The business’s quarterly revenue was up 12.0% on a year-over-year basis. As a group, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the company. Barclays raised their price objective on Elanco Animal Health from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Monday, September 23rd. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a research report on Thursday, September 19th. Finally, Piper Sandler reduced their target price on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, July 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Hold” and an average price target of $17.43.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.